Mark K. Oki
Mark K. Oki's purchase track record
Mark K. Oki has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/17/2025 | ACHV | $29K | +6.5% | +4.5% | +16.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Ascendiant Keeps Positive Outlook on Aytu, Raises Target to $15. Ascendiant Capital keeps a bullish view and raised its target to $15. The target sits well above the 52‑week high of $3.06, indicating a potential upside. The stock is currently trading near its support level of $2.17 and has an RSI of 45.6, suggesting neither overbought nor oversold conditions.
Transaction History
| ACHV | ▲ Buy | Option Exercise | 168,000 | $0 | 9/18/2025 | View on chart |
| ACHV | ▼ Sell | Open Market | 50,060 | $146K | 9/18/2025 | View on chart |
| ACHV | ▲ Buy | Open Market | 10,000 | $29K | 3/17/2025 | View on chart |
| AYTU | ▲ Buy | Grant | 90,000 | $21K | 11/18/2022 | View on chart |
| AYTU | ▲ Buy | Grant | 100,000 | $0 | 1/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Lisata Therapeutics adds Jeffrey Farrow to board
Lisata Therapeutics, the parent company of Achieve Life Sciences, has appointed Jeffrey Farrow to its board of directors. Farrow is a veteran in biopharma finance, bringing experience in capital markets and corporate strategy. This move signals a focus on strengthening the company's financial leadership and governance structure as it navigates its current market position.
Lisata Therapeutics adds Jeffrey Farrow to board. Lisata Therapeutics, the parent company of Achieve Life Sciences, has appointed Jeffrey Farrow to its board of directors. Farrow is a veteran in biopharma finance, bringing experience in capital markets and corporate strategy. This move signals a focus on strengthening the company's financial leadership and governance structure as it navigates its current market position.